Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
zydus heptiza
28 tablet
Sofosbuvir 400mg + Velpatasvir 100mg
Keep in cold place
Delivering To:
Overview
Sovihep V tablet is a combination of two antiviral drugs, Sofosbuvir and Velpatasvir. This medicine is used in the treatment of chronic Hepatitis C virus (HCV). Store this medicine at room temperature and keep it away from light and moisture. Chronic hepatitis C virus infection is the term used when the infection progresses into a stage that lasts for a long time. By stopping the hepatitis C virus from proliferating within your body, Sovihep V Tablet helps lower its number. This helps in infection control and speeds up your recovery. You must take this medication exactly as directed by your doctor, using the recommended dosage.
Hepatitis C
Chronic hepatitis C virus (HCV) infection
Sovihep V tablet may cause some serious and unwanted side effects that require immediate medical attention; otherwise, it can also lead to a higher risk. Do not forget to discuss the risks and benefits of this medication with your doctor.
Headache
Diarrhea
Nausea
Difficulty in breathing
Cough and chills
Loss of appetite
Muscle pain
Irregular heartbeat
Anemia
Take this medicine as prescribed by your doctor. Do not skip or miss your dosing schedule. This medicine can be taken with or without food. In case of an overdose, the doctor will provide emergency medical treatment.
Sovihep V works by blocking different steps in the reproduction of viruses. Sofosbuvir with Velpatasvir is an oral fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, and Velpatasvir, an NS5A replication complex inhibitor. Sofosbuvir is approved for the treatment of genotype 1, 2, 3, and 4 HCV infection with different regimens and durations depending on the HCV genotype. After the oral administration, the effect of this medicine can be observed in 2 to 4 hours.
Alcohol
unsafe
It is advisable not to consume alcohol while taking this medicine.
Pregnancy
consult your doctor
Do not take Sovihep V tablet without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not take Sovihep V tablet without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
It is advisable not to miss a dose of Sovihep V tablet. If you miss a scheduled dose of this medicine, contact your doctor immediately.
Sovihep V tablet is a combination of two antiviral medicines, Sofosbuvir and Velpatasvir. It works by removing the virus from the blood over time.
It works by blocking different steps in the reproduction of viruses.
Some common side effects are nausea, fatigue, headache, anemia, rashes, muscle pain, insomnia, dizziness, blurred vision, etc.
It is not known whether it is safe or not. Please consult your doctor before consuming alcohol.
Store this medicine at room temperature. Keep it away from heat and light.
Feld, J. J., Jacobson, I. M.,Hézode, C., Asselah, T., Ruane, P., Gruener, N., Chan, H. L. Y. (2015). Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. New England Journal of Medicine, 373(27), 2599–2607. https://doi.org/10.1056/NEJMoa1512610
Mangia, A., et al. (2020). Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5,552 patients from 12 cohorts. Liver International. Chandrashekhar, R., et al. (2019). Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase III study with minimal monitoring in India. Hepatology International.
Uemura, Y., et al. (2021). Real‑world clinical application of 12-week sofosbuvir/velpatasvir treatment for decompensated cirrhotic patients with genotype 1 and 2: a prospective, multicenter study. Journal of Clinical and Experimental Hepatology. (Open access). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680481/
Lee, S., et al. (2022). Efficacy and safety of sofosbuvir/velpatasvir ± ribavirin in genotype 3 compensated cirrhosis: a meta-analysis. World Journal of Hepatology, 14(6), 1248–1259. https://doi.org/10.4254/wjh.v14.i6.1248
Takehara, T., Sakamoto, N., Nishiguchi, S., et al. (2019). Sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase III trial. Journal of Gastroenterology, 54(1), 87–95. https://doi.org/10.1007/s00535-018-1503-x
